Alyeska Investment Group L.P. Has $4.10 Million Stock Holdings in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

Alyeska Investment Group L.P. increased its stake in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) by 16.4% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 142,113 shares of the company's stock after buying an additional 20,000 shares during the period. Alyeska Investment Group L.P. owned 0.52% of LENZ Therapeutics worth $4,103,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of LENZ. Northern Trust Corp boosted its holdings in shares of LENZ Therapeutics by 7.4% during the fourth quarter. Northern Trust Corp now owns 139,288 shares of the company's stock worth $4,021,000 after acquiring an additional 9,649 shares during the period. The Manufacturers Life Insurance Company boosted its stake in LENZ Therapeutics by 116.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 67,891 shares of the company's stock valued at $1,960,000 after purchasing an additional 36,582 shares during the period. Virtus ETF Advisers LLC acquired a new position in LENZ Therapeutics in the 4th quarter valued at $67,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of LENZ Therapeutics by 83.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 822,957 shares of the company's stock worth $23,760,000 after buying an additional 374,326 shares in the last quarter. Finally, Rock Springs Capital Management LP bought a new stake in shares of LENZ Therapeutics in the fourth quarter valued at about $846,000. Institutional investors and hedge funds own 54.32% of the company's stock.

Analyst Ratings Changes

LENZ has been the topic of a number of recent research reports. Citigroup raised their price target on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the stock a "buy" rating in a research report on Thursday, March 20th. Piper Sandler began coverage on shares of LENZ Therapeutics in a research report on Monday, April 14th. They issued an "overweight" rating and a $51.00 price target for the company. TD Cowen started coverage on LENZ Therapeutics in a research report on Tuesday, March 18th. They set a "buy" rating and a $60.00 price target on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a report on Thursday. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, LENZ Therapeutics has an average rating of "Buy" and an average target price of $46.60.

LENZ Therapeutics Trading Up 1.8 %

NASDAQ LENZ traded up $0.47 on Friday, hitting $26.34. 226,520 shares of the company's stock were exchanged, compared to its average volume of 186,422. The stock has a 50-day moving average of $24.56 and a 200-day moving average of $27.29. The stock has a market cap of $741.37 million, a price-to-earnings ratio of -14.88 and a beta of 0.41. LENZ Therapeutics, Inc. has a 52 week low of $14.42 and a 52 week high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.02. As a group, analysts predict that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current year.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.